for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AstraZeneca plc

AZN.L

Latest Trade

7,770.00GBp

Change

22.00(+0.28%)

Volume

5,398,309

Today's Range

7,644.00

 - 

7,805.00

52 Week Range

5,871.00

 - 

10,120.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
7,748.00
Open
7,703.00
Volume
5,398,309
3M AVG Volume
35.52
Today's High
7,805.00
Today's Low
7,644.00
52 Week High
10,120.00
52 Week Low
5,871.00
Shares Out (MIL)
1,312.31
Market Cap (MIL)
101,883.00
Forward P/E
25.54
Dividend (Yield %)
2.79

Next Event

AstraZeneca PLC at Redburn CEO Conference (Virtual)

Latest Developments

More

UK's MHRA Says It Got Health Dept Letter Requesting Review Of Oxford/AstraZeneca COVID-19 Vaccine Candidate

Health Canada - Lynparza Receives Health Canada Approval For Treatment Of Brca Or ATM Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

AstraZeneca Says Lokelma Label Update Approved In China For Patients With Hyperkalaemia On Chronic Haemodialysis

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AstraZeneca plc

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

Industry

Biotechnology & Drugs

Contact Info

1 Francis Crick Avenue

CB2 0AA

United Kingdom

+44.20.73045000

https://www.astrazeneca.com/Home

Executive Leadership

Leif Johansson

Independent Non-Executive Chairman of the Board

Pascal Soriot

Chief Executive Officer, Executive Director

Marc Dunoyer

Chief Financial Officer, Executive Director

Katarina Ageborg

Executive Vice President - Sustainability, Chief Compliance Officer

Fiona Cicconi

Executive Vice President - Human Resources

Key Stats

2.14 mean rating - 28 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

22.5K

2018

22.1K

2019

24.4K

2020(E)

26.5K
EPS (USD)

2017

4.280

2018

3.460

2019

3.500

2020(E)

4.054
Price To Earnings (TTM)
54.52
Price To Sales (TTM)
5.26
Price To Book (MRQ)
11.16
Price To Cash Flow (TTM)
21.63
Total Debt To Equity (MRQ)
183.18
LT Debt To Equity (MRQ)
153.78
Return on Investment (TTM)
5.59
Return on Equity (TTM)
3.93

Latest News

Latest News

Explainer: Will COVID-19 vaccines protect us? Does efficacy equal effectiveness?

The frontrunners in the COVID-19 vaccine race have emerged with different success rates for their shots in clinical trials, but what does that mean for the global fight against the pandemic?

Exclusive: Suspected North Korean hackers targeted COVID vaccine maker AstraZeneca - sources

Suspected North Korean hackers have tried to break into the systems of British drugmaker AstraZeneca in recent weeks, two people with knowledge of the matter told Reuters, as the company races to deploy its vaccine for the COVID-19 virus.

WHO says it needs to evaluate vaccine candidates on more than just a press release

The World Health Organization needs to evauate coronavirus vaccines and their immune responses based on more than just a press release, Kate O'Brien, WHO's director of immunisation vaccines and biologicals, said on Friday.

Britain and other nations press on with AstraZeneca vaccine amid trial questions

Britain asked its regulator on Friday to assess AstraZeneca's COVID-19 vaccine for a possible rollout, while the Philippines and Thailand secured millions of doses, giving the shot a vote of confidence after experts raised questions about trial data.

Breakingviews - AstraZeneca’s messaging warrants a review, too

AstraZeneca’s vaccine home run is in danger of turning into a curveball. The $134 billion drug giant is planning to review its Covid-19 vaccine candidate to clarify how effective it is. While it’s doing so, the UK group should probably do a separate review of how it communicates...

Top UK scientific adviser says AstraZeneca vaccine works

The British government's Chief Scientific Adviser Patrick Vallance said on Thursday the main point about the AstraZeneca vaccine against COVID-19 was that it worked, when asked about doubts that have been raised about the vaccine.

UPDATE 1-Philippines secures 2.6 mln doses of AstraZeneca's COVID-19 vaccine

* Government hopes to inoculate 2/3 of 108 population (Adds more details, quotes)

AstraZeneca CEO expects to run new global trial of COVID-19 vaccine - Bloomberg

AstraZeneca is likely to run an additional global trial to assess the efficacy of its COVID-19 vaccine using a lower dosage, its chief executive was quoted as saying on Thursday amid questions over the results of its late-stage study.

FOREX-Dollar edges down, set for weekly loss; Aussie and Kiwi rise

The dollar fell in early London trading on Friday and was on track for a weekly loss against a basket of currencies, even as the equity market rally ran out of steam as sentiment was hurt by doubts about AstraZeneca's COVID-19 vaccine.

European stocks set for fourth weekly gain but vaccine worries weigh

European shares edged lower on Friday as investors exercised caution ahead of a barrage of economic data due later in the day, while doubts about the effectiveness of AstraZeneca's COVID-19 vaccine also hit sentiment.

UK shares poised for weekly loss on vaccine doubts, Brexit concerns

London stocks slipped on Friday and looked set to post their first weekly loss for the month, as doubts over the efficacy of AstraZeneca's COVID-19 vaccine and concerns over a post-Brexit trade deal with the European Union weighed on sentiment.

No reason to worry about Oxford/Astra vaccine, UK minister says

British housing minister Robert Jenrick said there was no reason for anyone to be concerned about the data behind the Oxford and AstraZeneca vaccine and said the independent regulator would work to assess it.

Philippines secures 2.6 mln doses of AstraZeneca's COVID-19 vaccine

The Philippines will get 2.6 million shots of a potential COVID-19 vaccine developed by AstraZeneca under the country's first supply deal for a coronavirus vaccine, senior officials said on Friday.

AstraZeneca France says situation with its COVID-19 vaccine encouraging

The situation regarding the COVID-19 vaccine being developed by AstraZeneca is generally encouraging, even though a new trial will be needed, said AstraZeneca France president Olivier Nataf on Friday.

EMERGING MARKETS-Asian stocks mixed in subdued trading, India eyes GDP data

* Graphic: Foreign flows into Asian stocks https://tmsnrt.rs/3lKhL5I * Thai stocks eye best month since Jan. 2001 * India's GDP for the September quarter due at 1200 GMT By Shruti Sonal Nov 27 (Reuters) - Emerging Asian stock markets were mixed in subdued trading on Friday...

EMERGING MARKETS-Asian stocks mixed in subdued trading, India eyes GDP data

* Graphic: Foreign flows into Asian stocks https://tmsnrt.rs/3lKhL5I * Thai stocks eye best month since Jan. 2001 * India's GDP for the September quarter due at 1200 GMT By Shruti Sonal Nov 27 (Reuters) - Emerging Asian stock markets were mixed in subdued trading on Friday...

UK Stocks-Factors to watch on Nov 27

Nov 27 - Britain's FTSE 100 index is seen opening 19 points lower at 6,344 on Friday, according to financial bookmakers. * ASTRAZENECA: AstraZeneca is likely to run an additional global trial to assess the efficacy of its COVID-19 vaccine using a lower dosage, its chief...

Britain asks regulator to assess Oxford/AstraZeneca COVID-19 vaccine

Britain on Friday asked its medicine regulator to assess Oxford University and AstraZeneca's COVID-19 vaccine candidate for temporary supply, a step towards beginning a roll-out before the end of the year.

Australia shares set to fall on fears of slow recovery, vaccine woes

Australian shares were poised to open lower on Friday as rising global COVID-19 cases stoked fears of a long-drawn economic recovery, while concerns over the results of one potential vaccine also dampened sentiment. British drugmaker AstraZeneca said it would likely run...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up